NURO Quote, Financials, Valuation and Earnings

electroCore has a net margin of -256.8% compared to NeuroMetrix's net margin of -38.1%. NeuroMetrix's return on equity of -41.7% beat electroCore's return on equity of -144.52%.

NeuroMetrix has a consensus price target of --, signalling upside risk potential of 10111.9%. On the other hand electroCore has an analysts' consensus of $25.47 which suggests that it could grow by 51.97%. Given that NeuroMetrix has higher upside potential than electroCore, analysts believe NeuroMetrix is more attractive than electroCore.

NeuroMetrix has a beta of 2.182, which suggesting that the stock is 118.234% more volatile than S&P 500. In comparison electroCore has a beta of 0.574, suggesting its less volatile than the S&P 500 by 42.566%.

NeuroMetrix has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. electroCore offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. NeuroMetrix pays -- of its earnings as a dividend. electroCore pays out -- of its earnings as a dividend.

NeuroMetrix quarterly revenues are $587.3K, which are smaller than electroCore quarterly revenues of $6.6M. NeuroMetrix's net income of -$1.5M is higher than electroCore's net income of -$2.5M. Notably, NeuroMetrix's price-to-earnings ratio is -- while electroCore's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for NeuroMetrix is 1.82x versus 5.10x for electroCore. Usually stocks with elevated PS ratios are considered overvalued.

Retractable Technologies has a net margin of -256.8% compared to NeuroMetrix's net margin of -18.58%. NeuroMetrix's return on equity of -41.7% beat Retractable Technologies's return on equity of -16.83%.

NeuroMetrix has a consensus price target of --, signalling upside risk potential of 10111.9%. On the other hand Retractable Technologies has an analysts' consensus of -- which suggests that it could fall by --. Given that NeuroMetrix has higher upside potential than Retractable Technologies, analysts believe NeuroMetrix is more attractive than Retractable Technologies.

NeuroMetrix has a beta of 2.182, which suggesting that the stock is 118.234% more volatile than S&P 500. In comparison Retractable Technologies has a beta of 1.979, suggesting its more volatile than the S&P 500 by 97.877%.

NeuroMetrix has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Retractable Technologies offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. NeuroMetrix pays -- of its earnings as a dividend. Retractable Technologies pays out -3.32% of its earnings as a dividend.

NeuroMetrix quarterly revenues are $587.3K, which are smaller than Retractable Technologies quarterly revenues of $10.3M. NeuroMetrix's net income of -$1.5M is higher than Retractable Technologies's net income of -$1.9M. Notably, NeuroMetrix's price-to-earnings ratio is -- while Retractable Technologies's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for NeuroMetrix is 1.82x versus 0.50x for Retractable Technologies. Usually stocks with elevated PS ratios are considered overvalued.

Catheter Precision has a net margin of -256.8% compared to NeuroMetrix's net margin of -4291.67%. NeuroMetrix's return on equity of -41.7% beat Catheter Precision's return on equity of -65.84%.

NeuroMetrix has a consensus price target of --, signalling upside risk potential of 10111.9%. On the other hand Catheter Precision has an analysts' consensus of -- which suggests that it could grow by 377.33%. Given that NeuroMetrix has higher upside potential than Catheter Precision, analysts believe NeuroMetrix is more attractive than Catheter Precision.

NeuroMetrix has a beta of 2.182, which suggesting that the stock is 118.234% more volatile than S&P 500. In comparison Catheter Precision has a beta of -0.210, suggesting its less volatile than the S&P 500 by 121.025%.

NeuroMetrix has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Catheter Precision offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. NeuroMetrix pays -- of its earnings as a dividend. Catheter Precision pays out -- of its earnings as a dividend.

NeuroMetrix quarterly revenues are $587.3K, which are larger than Catheter Precision quarterly revenues of $96K. NeuroMetrix's net income of -$1.5M is higher than Catheter Precision's net income of -$4.1M. Notably, NeuroMetrix's price-to-earnings ratio is -- while Catheter Precision's PE ratio is 0.48x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for NeuroMetrix is 1.82x versus 1.12x for Catheter Precision. Usually stocks with elevated PS ratios are considered overvalued.

Xtant Medical Holdings has a net margin of -256.8% compared to NeuroMetrix's net margin of -17.98%. NeuroMetrix's return on equity of -41.7% beat Xtant Medical Holdings's return on equity of -35.98%.

NeuroMetrix has a consensus price target of --, signalling upside risk potential of 10111.9%. On the other hand Xtant Medical Holdings has an analysts' consensus of -- which suggests that it could grow by 418.19%. Given that NeuroMetrix has higher upside potential than Xtant Medical Holdings, analysts believe NeuroMetrix is more attractive than Xtant Medical Holdings.

NeuroMetrix has a beta of 2.182, which suggesting that the stock is 118.234% more volatile than S&P 500. In comparison Xtant Medical Holdings has a beta of 0.357, suggesting its less volatile than the S&P 500 by 64.342%.

NeuroMetrix has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Xtant Medical Holdings offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. NeuroMetrix pays -- of its earnings as a dividend. Xtant Medical Holdings pays out -- of its earnings as a dividend.

NeuroMetrix quarterly revenues are $587.3K, which are smaller than Xtant Medical Holdings quarterly revenues of $27.9M. NeuroMetrix's net income of -$1.5M is higher than Xtant Medical Holdings's net income of -$5M. Notably, NeuroMetrix's price-to-earnings ratio is -- while Xtant Medical Holdings's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for NeuroMetrix is 1.82x versus 0.51x for Xtant Medical Holdings. Usually stocks with elevated PS ratios are considered overvalued.